Skip to Content
End of Year Sale. Save up to twenty-five percent off sitewide.End of Year Sale. Save up to twenty-five percent off sitewide.

Management of Medication-related Osteonecrosis of the Jaw, An Issue of Oral and Maxillofacial Clinics of North America, 1st Edition

Author :
Salvatore L. Ruggiero
Date of Publication: 11/2015
Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive ...view more
Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive therapies for the treatment of malignant osteolytic bone disease; Clinical presentation and staging of antiresorptive agent-induced osteonecrosis of the jaw; Epidemiology and risk factors of antiresorptive agent-induced osteonecrosis of the jaw; Basic science research of antiresorptive agent-induced osteonecrosis of the jaw: an update; Pathophysiology of antiresorptive agent-induced osteonecrosis of the jaw: what we know and what we don’t know; The genetics of osteonecrosis of the jaw; Preventive strategies for patients at risk of antiresorptive agent-induced osteonecrosis of the jaw; Non-operative and operative therapies for treatment of antiresorptive agent-induced osteonecrosis of the jaw; The role of anti-angiogenic therapy in the development of osteonecrosis of the jaw; Antiresorptive therapies: what they are and how do they work, and more!
Add to Cart
Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive therapies for the treatment of malignant osteolytic bone disease; Clinical presentation and staging of antiresorptive agent-induced osteonecrosis of the jaw; Epidemiology and risk factors of antiresorptive agent-induced osteonecrosis of the jaw; Basic science research of antiresorptive agent-induced osteonecrosis of the jaw: an update; Pathophysiology of antiresorptive agent-induced osteonecrosis of the jaw: what we know and what we don’t know; The genetics of osteonecrosis of the jaw; Preventive strategies for patients at risk of antiresorptive agent-induced osteonecrosis of the jaw; Non-operative and operative therapies for treatment of antiresorptive agent-induced osteonecrosis of the jaw; The role of anti-angiogenic therapy in the development of osteonecrosis of the jaw; Antiresorptive therapies: what they are and how do they work, and more!

Author Information
By Salvatore L. Ruggiero, DMD, MD, FACS, New York Center of Oral and Maxillofacial Surgery